Published in Clin Interv Aging on January 01, 2008
Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality. Am Heart J (2015) 0.84
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis. Mediators Inflamm (2016) 0.78
Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium. Curr Signal Transduct Ther (2012) 0.75
Inflammatory cardiovascular risk biomarkers: update on novelties and limitations. Mediators Inflamm (2012) 0.75
Antioxidant and anti-inflammatory effects of flavocoxid in high-cholesterol-fed rabbits. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.75
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med (2007) 33.21
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med (1997) 18.85
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med (2000) 18.04
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med (2002) 16.23
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
C-reactive protein: a critical update. J Clin Invest (2003) 11.77
SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS. J Exp Med (1930) 10.97
The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol (2006) 9.61
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA (1998) 7.67
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med (2001) 7.51
Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw (2006) 7.19
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ (2000) 6.10
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation (1998) 4.89
Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation (2000) 4.81
Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA (2003) 4.76
Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation (2003) 4.67
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation (1999) 4.40
Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA (2007) 4.25
Alcohol consumption and mortality among women. N Engl J Med (1995) 4.22
Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation (2003) 4.09
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation (2002) 3.96
Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90
Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 3.69
Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66
Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature (1998) 3.48
Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation (2006) 3.15
Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation (2002) 3.14
Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation (1998) 2.83
Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 2.78
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med (2002) 2.77
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 2.76
Physical activity and hemostatic and inflammatory variables in elderly men. Circulation (2002) 2.75
Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med (2002) 2.70
Association between physical activity and markers of inflammation in a healthy elderly population. Am J Epidemiol (2001) 2.68
C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol (2005) 2.64
The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure (1999) 2.64
C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J (2000) 2.59
Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation (2003) 2.52
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep (2002) 2.47
Weight loss reduces C-reactive protein levels in obese postmenopausal women. Circulation (2002) 2.46
C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 2.43
Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med (2004) 2.39
Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med (Berl) (2005) 2.29
Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation (2003) 2.28
Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med (2003) 2.22
C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A (2002) 2.20
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 2.16
Relationship between physical activity and inflammation among apparently healthy middle-aged and older US adults. Arch Intern Med (2002) 2.12
Does exercise reduce inflammation? Physical activity and C-reactive protein among U.S. adults. Epidemiology (2002) 2.11
Function of C-reactive protein. Ann Med (2000) 2.10
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet (2005) 2.00
C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension (2004) 1.99
Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation (1999) 1.99
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet (2003) 1.98
Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation (2002) 1.94
C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.92
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol (2000) 1.88
Infections, inflammation, and the risk of coronary heart disease. Circulation (2000) 1.77
Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol (2002) 1.73
C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol (2000) 1.70
The associations between physical activity and inflammatory markers in high-functioning older persons: MacArthur Studies of Successful Aging. J Am Geriatr Soc (2003) 1.68
Local release of C-reactive protein from vulnerable plaque or coronary arterial wall injured by stenting. J Am Coll Cardiol (2005) 1.68
Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine (1992) 1.64
Absence of P-selectin delays fatty streak formation in mice. J Clin Invest (1997) 1.63
Alcohol consumption and plasma concentration of C-reactive protein. Circulation (2003) 1.60
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation (2001) 1.58
C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res (2004) 1.56
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Qualitative and quantitative effects of APOE genetic variation on plasma C-reactive protein, LDL-cholesterol, and apoE protein. Genes Immun (2006) 1.44
Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol (2003) 1.44
C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem (2003) 1.42
Associations between cardiorespiratory fitness and C-reactive protein in men. Arterioscler Thromb Vasc Biol (2002) 1.42
Expression of C-reactive protein by alveolar macrophages. J Immunol (1996) 1.38
C-reactive protein in atherosclerotic lesions: its origin and pathophysiological significance. Am J Pathol (2005) 1.37
Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun (2002) 1.37
C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis (2005) 1.36
Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care (2007) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
C-reactive protein (CRP) gene polymorphisms, CRP levels, and risk of incident coronary heart disease in two nested case-control studies. PLoS One (2008) 1.31
A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis (2005) 1.26
C-reactive protein promotes monocyte chemoattractant protein-1--mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation (2004) 1.25
Genetic variability at the leptin receptor (LEPR) locus is a determinant of plasma fibrinogen and C-reactive protein levels. Atherosclerosis (2006) 1.22
Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol (2001) 1.18
C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med (1986) 1.18
IL-6 gene variation is associated with IL-6 and C-reactive protein levels but not cardiovascular outcomes in the Cardiovascular Health Study. Hum Genet (2007) 1.18
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol (2002) 1.15
Cardiorespiratory fitness and C-reactive protein among a tri-ethnic sample of women. Circulation (2002) 1.15
Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol (2007) 1.14
C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr (2003) 1.14
Inflammation, thrombosis and acute coronary syndromes. Diab Vasc Dis Res (2005) 1.12
Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol (2001) 1.10
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature (2005) 3.02
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
[Statin treatment in primary and secondary prevention--a statement]. Rev Med Suisse (2014) 2.55
Inferior vena cava parameters predict re-admission in ischaemic heart failure. Eur J Clin Invest (2014) 2.01
Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2006) 1.99
Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res (2003) 1.99
Thrombin stimulates human endothelial arginase enzymatic activity via RhoA/ROCK pathway: implications for atherosclerotic endothelial dysfunction. Circulation (2004) 1.90
The specific role of chemokines in atherosclerosis. Thromb Haemost (2007) 1.62
Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation (2012) 1.57
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res (2005) 1.49
Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol (2005) 1.49
Receptor activator of NF- κB ligand (RANKL) increases the release of neutrophil products associated with coronary vulnerability. Thromb Haemost (2011) 1.48
Late cardiac tamponade after percutaneous closure of a patent foramen ovale. Eur J Echocardiogr (2005) 1.41
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Circulation (2005) 1.40
Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. Eur J Cardiovasc Prev Rehabil (2010) 1.33
Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol (2012) 1.32
Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation (2006) 1.31
A novel RANTES antagonist prevents progression of established atherosclerotic lesions in mice. Arterioscler Thromb Vasc Biol (2008) 1.30
CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol (2008) 1.25
CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol (2009) 1.24
Reduced connexin43 expression inhibits atherosclerotic lesion formation in low-density lipoprotein receptor-deficient mice. Circulation (2003) 1.22
Toward immunomodulatory and anti-inflammatory properties of statins. Trends Cardiovasc Med (2005) 1.22
Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol (2002) 1.21
A DNA resequencing array for pathogenic mutation detection in hypertrophic cardiomyopathy. Hum Mutat (2008) 1.21
Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. J Mol Cell Cardiol (2009) 1.20
Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis (2006) 1.19
Tumor necrosis factor-alpha (TNF-alpha) induces integrin CD11b/CD18 (Mac-1) up-regulation and migration to the CC chemokine CCL3 (MIP-1alpha) on human neutrophils through defined signalling pathways. Cell Signal (2007) 1.16
The inflammatory response as a target to reduce myocardial ischaemia and reperfusion injury. Thromb Haemost (2009) 1.14
CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. Thromb Haemost (2010) 1.13
Potential antiinflammatory and immunomodulatory effects of statins in rheumatologic therapy. Arthritis Rheum (2006) 1.13
Atherosclerosis: anti-inflammatory and immunomodulatory activities of statins. Autoimmun Rev (2003) 1.12
Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res (2003) 1.07
PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res (2007) 1.06
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. Mediators Inflamm (2009) 1.05
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J (2011) 1.05
Update on statin-mediated anti-inflammatory activities in atherosclerosis. Semin Immunopathol (2009) 1.04
Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction. Antioxid Redox Signal (2012) 1.04
Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circ Heart Fail (2011) 1.03
Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis (2009) 1.01
Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. Stroke (2010) 1.00
Toll-like receptor 7 protects from atherosclerosis by constraining "inflammatory" macrophage activation. Circulation (2012) 0.99
In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. Eur Heart J (2009) 0.99
Insulin resistance: a proinflammatory state mediated by lipid-induced signaling dysfunction and involved in atherosclerotic plaque instability. Mediators Inflamm (2008) 0.99
Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J (2012) 0.98
CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. Eur Heart J (2011) 0.98
Coronary vasomotor control in obesity and morbid obesity: contrasting flow responses with endocannabinoids, leptin, and inflammation. JACC Cardiovasc Imaging (2012) 0.98
Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis (2009) 0.97
Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum (2010) 0.97
Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur Heart J (2011) 0.96
The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am J Respir Crit Care Med (2011) 0.96
Inflammation in the pathophysiology of essential hypertension. J Nephrol (2010) 0.95
Role of matrix metalloproteinase-8 in atherosclerosis. Mediators Inflamm (2013) 0.95
Role of Toll-like receptor 4 on pancreatic and pulmonary injury in a mice model of acute pancreatitis associated with endotoxemia. Crit Care Med (2004) 0.94
Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr Drug Targets Cardiovasc Haematol Disord (2005) 0.93
Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res (2007) 0.93
Shear stress modulates the expression of the atheroprotective protein Cx37 in endothelial cells. J Mol Cell Cardiol (2012) 0.92
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. Am J Physiol Endocrinol Metab (2011) 0.92
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J (2011) 0.91
Inflammation and atherosclerosis. Herz (2004) 0.89
Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis (2010) 0.89
Treatment with Evasin-3 reduces atherosclerotic vulnerability for ischemic stroke, but not brain injury in mice. J Cereb Blood Flow Metab (2012) 0.88
Differential expression patterns of proinflammatory and antiinflammatory mediators during atherogenesis in mice. Arterioscler Thromb Vasc Biol (2004) 0.88
Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler Thromb Vasc Biol (2010) 0.88
"In vivo" imaging of atherosclerosis. Atherosclerosis (2012) 0.88
The immune response is involved in atherosclerotic plaque calcification: could the RANKL/RANK/OPG system be a marker of plaque instability? Clin Dev Immunol (2007) 0.87
Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. J Med Genet (2011) 0.86
Swimming prevents vulnerable atherosclerotic plaque development in hypertensive 2-kidney, 1-clip mice by modulating angiotensin II type 1 receptor expression independently from hemodynamic changes. Hypertension (2009) 0.85
Role of mitogen-activated protein kinase pathways in multifactorial adverse cardiac remodeling associated with metabolic syndrome. Mediators Inflamm (2013) 0.85
Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J (2010) 0.85
C-reactive protein (CRP) induces chemokine secretion via CD11b/ICAM-1 interaction in human adherent monocytes. J Leukoc Biol (2008) 0.85
Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). Sleep Breath (2010) 0.85
Update on the role of cannabinoid receptors after ischemic stroke. Mediators Inflamm (2012) 0.85
The angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis: a potential target for treating thrombotic diseases. Thromb Haemost (2012) 0.84
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost (2014) 0.84
Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice. Thromb Haemost (2013) 0.84
Impact of propofol anaesthesia on cytokine expression profiles in the developing rat brain: a randomised placebo-controlled experimental in-vivo study. Eur J Anaesthesiol (2015) 0.84
The vulnerable coronary plaque: update on imaging technologies. Thromb Haemost (2013) 0.84
An oral formulation of angiotensin-(1-7) reverses corpus cavernosum damages induced by hypercholesterolemia. J Sex Med (2013) 0.83
Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? Nat Clin Pract Nephrol (2006) 0.83
Myocardial infarction quantification with Manganese-Enhanced MRI (MEMRI) in mice using a 3T clinical scanner. NMR Biomed (2010) 0.83
New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Rev Cardiovasc Ther (2010) 0.83
Dual benefit of reduced Cx43 on atherosclerosis in LDL receptor-deficient mice. Cell Commun Adhes (2003) 0.83
Atherosclerosis is an inflammatory disease. Semin Immunopathol (2009) 0.82
Treatment with the CC chemokine-binding protein Evasin-4 improves post-infarction myocardial injury and survival in mice. Thromb Haemost (2013) 0.82
Methylene blue: potential use of an antique molecule in vasoplegic syndrome during cardiac surgery. Expert Rev Cardiovasc Ther (2011) 0.82
Inflammation is a key pathophysiological feature of metabolic syndrome. Mediators Inflamm (2013) 0.82
Elevated E-selectin and diastolic blood pressure in diabetic children. Eur J Clin Invest (2011) 0.82
Mas receptor deficiency is associated with worsening of lipid profile and severe hepatic steatosis in ApoE-knockout mice. Am J Physiol Regul Integr Comp Physiol (2013) 0.82
Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab (2009) 0.82
Soluble CD40 ligand in prediction of acute severe pancreatitis. World J Gastroenterol (2006) 0.81
Atorvastatin treatment and vaccination efficacy. J Clin Pharmacol (2007) 0.81
[A Swiss multicentric project to improve the prevention of cardiovascular event recurrence after acute coronary syndromes]. Rev Med Suisse (2010) 0.81
Update on the protective molecular pathways improving pancreatic beta-cell dysfunction. Mediators Inflamm (2013) 0.81
Update on the treatments of non-alcoholic fatty liver disease (NAFLD). Cardiovasc Hematol Disord Drug Targets (2009) 0.80
Antiapolipoprotein A-1 IgG chronotropic effects require nongenomic action of aldosterone on L-type calcium channels. Endocrinology (2012) 0.80
Role of matrix metalloproteinases in animal models of ischemic stroke. Curr Vasc Pharmacol (2015) 0.80
Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thromb Haemost (2013) 0.80
Role of the renin-angiotensin system on abdominal aortic aneurysms. Eur J Clin Invest (2013) 0.79